Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module.

摘要: Statistics Canada (Ottawa, Ontario, Canada) is in the process of developing Population Health Model to simulate health and common illnesses Canadians. The incorporates a lung cancer module that based on contemporary Canadian practice. This microsimulation model can be used estimate total direct care costs treating all cases diagnosed evaluate cost cost-effectiveness new therapeutic interventions as they are introduced into Gemcitabine, nucleoside analogue with broad spectrum antitumor activity, about market. has been gemcitabine management over range drug doses per treatment cycle starting at 1,000 mg/m2 weekly x 3, well potential survival benefits. stage IV non-small cell (NSCLC) patients treated an international trial (EO-18) was gain relative NSCLC managed best supportive randomized conducted by National Cancer Institute (BR 5). Sensitivity analyses were performed assuming 25% or 50% less than reported EO-18 trial. perspective economic analysis government payer universal system, expressed 1993 dollars. Based apparent advantage comparison care, life-year gained ranged from $632 $9,285, depending dose cycle. At highest (2,000 mg/m2) reduced compared result, estimated $17,390. From these estimates appears cost-effective intervention for advanced NSCLC.